Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer

This phase II study evaluated the response rate and tolerability of gemcitabine–oxaliplatin chemotherapy in non-small-cell lung cancer (NSCLC) patients. Chemonaive patients with stage IIIB or IV NSCLC received gemcitabine 1000 mg m(−2) on days 1 and 8, followed by oxaliplatin 130 mg m(−2) on day 1....

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Cappuzzo, F, Novello, S, De Marinis, F, Franciosi, V, Maur, M, Ceribelli, A, Lorusso, V, Barbieri, F, Castaldini, L, Crucitta, E, Marini, L, Bartolini, S, Scagliotti, G V, Crinò, L
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group 2005
Предметы:
Clinical Study
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC2361475/
https://ncbi.nlm.nih.gov/pubmed/15956971
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6602667
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы